APO Research
Talk to an analyst

APO RESEARCH · REPORT

Acute Vulvovaginal Candidiasis Treatment

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Acute Vulvovaginal Candidiasis Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

20 December 2025195 pages

Choose your research edition.

Industry ResearchAcute Vulvovaginal Candidiasis Treatment Industry Research Report 2026139 pages · $2,950 USDIndustry Growth & TrendsGlobal Acute Vulvovaginal Candidiasis Treatment Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Acute Vulvovaginal Candidiasis Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Acute Vulvovaginal Candidiasis Treatment Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Acute Vulvovaginal Candidiasis Treatment Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global Acute Vulvovaginal Candidiasis Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Acute Vulvovaginal Candidiasis Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Acute Vulvovaginal Candidiasis Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Acute Vulvovaginal Candidiasis Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Acute Vulvovaginal Candidiasis Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Acute Vulvovaginal Candidiasis Treatment include Sandoz International GmbH, Novartis AG, Mylan N.V., Pfizer, Inc., Bayer AG., Scynexis, Inc, Phathom Pharmaceutical, Inc, Pacgen Life Science Corporation and NovaDigm Therapeutics, Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Acute Vulvovaginal Candidiasis Treatment market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Acute Vulvovaginal Candidiasis Treatment and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Acute Vulvovaginal Candidiasis Treatment revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Acute Vulvovaginal Candidiasis Treatment market size, projected growth trends, production technologies, key applications, and end-use industries.

Acute Vulvovaginal Candidiasis Treatment Segment by Company

Sandoz International GmbH

Novartis AG

Mylan N.V.

Pfizer, Inc.

Bayer AG.

Scynexis, Inc

Phathom Pharmaceutical, Inc

Pacgen Life Science Corporation

NovaDigm Therapeutics, Inc

Mycovia Pharmaceuticals, Inc

Lupin

Grupo Ferrer Internacional, S.A

Cidara Therapeutics, Inc

Cadila Pharmaceuticals

Bristol-Myers Squibb Company

Basilea Pharmaceutica Ltd

Astellas Pharma Inc

Amplyx Pharmaceuticals Inc

Amneal Pharmaceuticals LLC

Accord Healthcare Ltd

Acute Vulvovaginal Candidiasis Treatment Segment by Type

Nystatin

Ketoconazole

Terconazole

Terbinafine

Clotrimazole

Fluconazole

Others

Acute Vulvovaginal Candidiasis Treatment Segment by Application

Retail Pharmacies

Online Pharmacies

Hospital Pharmacies

Acute Vulvovaginal Candidiasis Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Acute Vulvovaginal Candidiasis Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Acute Vulvovaginal Candidiasis Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Acute Vulvovaginal Candidiasis Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Acute Vulvovaginal Candidiasis Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Acute Vulvovaginal Candidiasis Treatment industry.

Chapter 3: Detailed analysis of Acute Vulvovaginal Candidiasis Treatment companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Acute Vulvovaginal Candidiasis Treatmentrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Nystatin Table 3. Key Players of Ketoconazole Table 4. Key Players of Terconazole Table 3. Key Players of Terbinafine Table 4. Key Players of Clotrimazole Table 5. Key Players of Fluconazole Table 6. Key Players of Others Table 7. Global Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 8. Key Players of Retail Pharmacies Table 9. Key Players of Online Pharmacies Table 10. Key Players of Hospital Pharmacies Table 11. Global Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 12. Global Acute Vulvovaginal Candidiasis Treatment Market Size by Region (2021-2026) & (US$ Million) Table 13. Global Acute Vulvovaginal Candidiasis Treatment Market Share by Region (2021-2026) Table 14. Global Acute Vulvovaginal Candidiasis Treatment Market Size by Region (2027-2032) & (US$ Million) Table 15. Global Acute Vulvovaginal Candidiasis Treatment Market Share by Region (2027-2032) Table 16. Acute Vulvovaginal Candidiasis Treatment Industry Trends Table 17. Acute Vulvovaginal Candidiasis Treatment Industry Drivers Table 18. Acute Vulvovaginal Candidiasis Treatment Industry Opportunities and Challenges Table 19. Acute Vulvovaginal Candidiasis Treatment Industry Restraints Table 20. Global Acute Vulvovaginal Candidiasis Treatment Revenue by Company (US$ Million) & (2021-2026) Table 21. Global Acute Vulvovaginal Candidiasis Treatment Revenue Market Share by Company (2021-2026) Table 22. Global Acute Vulvovaginal Candidiasis Treatment Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 23. Global Acute Vulvovaginal Candidiasis Treatment Key Company Head Office and Area Served Table 24. Global Acute Vulvovaginal Candidiasis Treatment Company, Product Type & Application Table 25. Global Acute Vulvovaginal Candidiasis Treatment Company Establishment Date Table 26. Global Company Market Concentration Ratio (CR5 and HHI) Table 27. Global Acute Vulvovaginal Candidiasis Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 28. Global Acute Vulvovaginal Candidiasis Treatment Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2021-2026) & (US$ Million) Table 30. Global Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2027-2032) & (US$ Million) Table 31. Global Acute Vulvovaginal Candidiasis Treatment Revenue Market Share by Type (2021-2026) Table 32. Global Acute Vulvovaginal Candidiasis Treatment Revenue Market Share by Type (2027-2032) Table 33. Global Acute Vulvovaginal Candidiasis Treatment Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2021-2026) & (US$ Million) Table 35. Global Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2027-2032) & (US$ Million) Table 36. Global Acute Vulvovaginal Candidiasis Treatment Revenue Market Share by Application (2021-2026) Table 37. Global Acute Vulvovaginal Candidiasis Treatment Revenue Market Share by Application (2027-2032) Table 38. Sandoz International GmbH Company Information Table 39. Sandoz International GmbH Business Overview Table 40. Sandoz International GmbH Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Sandoz International GmbH Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 42. Sandoz International GmbH Recent Development Table 43. Novartis AG Company Information Table 44. Novartis AG Business Overview Table 45. Novartis AG Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Novartis AG Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 47. Novartis AG Recent Development Table 48. Mylan N.V. Company Information Table 49. Mylan N.V. Business Overview Table 50. Mylan N.V. Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. Mylan N.V. Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 52. Mylan N.V. Recent Development Table 53. Pfizer, Inc. Company Information Table 54. Pfizer, Inc. Business Overview Table 55. Pfizer, Inc. Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. Pfizer, Inc. Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 57. Pfizer, Inc. Recent Development Table 58. Bayer AG. Company Information Table 59. Bayer AG. Business Overview Table 60. Bayer AG. Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. Bayer AG. Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 62. Bayer AG. Recent Development Table 63. Scynexis, Inc Company Information Table 64. Scynexis, Inc Business Overview Table 65. Scynexis, Inc Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. Scynexis, Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 67. Scynexis, Inc Recent Development Table 68. Phathom Pharmaceutical, Inc Company Information Table 69. Phathom Pharmaceutical, Inc Business Overview Table 70. Phathom Pharmaceutical, Inc Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. Phathom Pharmaceutical, Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 72. Phathom Pharmaceutical, Inc Recent Development Table 73. Pacgen Life Science Corporation Company Information Table 74. Pacgen Life Science Corporation Business Overview Table 75. Pacgen Life Science Corporation Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. Pacgen Life Science Corporation Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 77. Pacgen Life Science Corporation Recent Development Table 78. NovaDigm Therapeutics, Inc Company Information Table 79. NovaDigm Therapeutics, Inc Business Overview Table 80. NovaDigm Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. NovaDigm Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 82. NovaDigm Therapeutics, Inc Recent Development Table 83. Mycovia Pharmaceuticals, Inc Company Information Table 84. Mycovia Pharmaceuticals, Inc Business Overview Table 85. Mycovia Pharmaceuticals, Inc Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 86. Mycovia Pharmaceuticals, Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 87. Mycovia Pharmaceuticals, Inc Recent Development Table 88. Lupin Company Information Table 89. Lupin Business Overview Table 90. Lupin Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 91. Lupin Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 92. Lupin Recent Development Table 93. Grupo Ferrer Internacional, S.A Company Information Table 94. Grupo Ferrer Internacional, S.A Business Overview Table 95. Grupo Ferrer Internacional, S.A Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 96. Grupo Ferrer Internacional, S.A Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 97. Grupo Ferrer Internacional, S.A Recent Development Table 98. Cidara Therapeutics, Inc Company Information Table 99. Cidara Therapeutics, Inc Business Overview Table 100. Cidara Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 101. Cidara Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 102. Cidara Therapeutics, Inc Recent Development Table 103. Cadila Pharmaceuticals Company Information Table 104. Cadila Pharmaceuticals Business Overview Table 105. Cadila Pharmaceuticals Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 106. Cadila Pharmaceuticals Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 107. Cadila Pharmaceuticals Recent Development Table 108. Bristol-Myers Squibb Company Company Information Table 109. Bristol-Myers Squibb Company Business Overview Table 110. Bristol-Myers Squibb Company Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 111. Bristol-Myers Squibb Company Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 112. Bristol-Myers Squibb Company Recent Development Table 113. Basilea Pharmaceutica Ltd Company Information Table 114. Basilea Pharmaceutica Ltd Business Overview Table 115. Basilea Pharmaceutica Ltd Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 116. Basilea Pharmaceutica Ltd Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 117. Basilea Pharmaceutica Ltd Recent Development Table 118. Astellas Pharma Inc Company Information Table 119. Astellas Pharma Inc Business Overview Table 120. Astellas Pharma Inc Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 121. Astellas Pharma Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 122. Astellas Pharma Inc Recent Development Table 123. Amplyx Pharmaceuticals Inc Company Information Table 124. Amplyx Pharmaceuticals Inc Business Overview Table 125. Amplyx Pharmaceuticals Inc Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 126. Amplyx Pharmaceuticals Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 127. Amplyx Pharmaceuticals Inc Recent Development Table 128. Amneal Pharmaceuticals LLC Company Information Table 129. Amneal Pharmaceuticals LLC Business Overview Table 130. Amneal Pharmaceuticals LLC Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 131. Amneal Pharmaceuticals LLC Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 132. Amneal Pharmaceuticals LLC Recent Development Table 133. Accord Healthcare Ltd Company Information Table 134. Accord Healthcare Ltd Business Overview Table 135. Accord Healthcare Ltd Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 136. Accord Healthcare Ltd Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 137. Accord Healthcare Ltd Recent Development Table 138. North America Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2021-2026) & (US$ Million) Table 139. North America Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2027-2032) & (US$ Million) Table 140. North America Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2021-2026) & (US$ Million) Table 141. North America Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2027-2032) & (US$ Million) Table 142. North America Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 143. North America Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2021-2026) Table 144. North America Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2027-2032) Table 145. Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2021-2026) & (US$ Million) Table 146. Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2027-2032) & (US$ Million) Table 147. Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2021-2026) & (US$ Million) Table 148. Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2027-2032) & (US$ Million) Table 149. Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 150. Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2021-2026) Table 151. Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2027-2032) Table 152. China Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2021-2026) & (US$ Million) Table 153. China Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2027-2032) & (US$ Million) Table 154. China Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2021-2026) & (US$ Million) Table 155. China Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2027-2032) & (US$ Million) Table 156. Asia Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2021-2026) & (US$ Million) Table 157. Asia Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2027-2032) & (US$ Million) Table 158. Asia Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2021-2026) & (US$ Million) Table 159. Asia Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2027-2032) & (US$ Million) Table 160. Asia Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 161. Asia Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2021-2026) Table 162. Asia Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2027-2032) Table 163. South America, Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2021-2026) & (US$ Million) Table 164. South America, Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2027-2032) & (US$ Million) Table 165. South America, Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2021-2026) & (US$ Million) Table 166. South America, Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2027-2032) & (US$ Million) Table 167. South America, Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 168. South America, Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2021-2026) Table 169. South America, Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2027-2032) Table 170. Research Programs/Design for This Report Table 171. Authors List of This Report Table 172. Secondary Sources Table 173. Primary Sources List of Figures Figure 1. Acute Vulvovaginal Candidiasis Treatment Product Image Figure 2. Global Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Acute Vulvovaginal Candidiasis Treatment Market Share by Type: 2025 VS 2032 Figure 4. Nystatin Image Figure 5. Ketoconazole Image Figure 6. Terconazole Image Figure 7. Terbinafine Image Figure 8. Clotrimazole Image Figure 9. Fluconazole Image Figure 10. Others Image Figure 11. Global Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 12. Global Acute Vulvovaginal Candidiasis Treatment Market Share by Application: 2025 VS 2032 Figure 13. Retail Pharmacies Image Figure 14. Online Pharmacies Image Figure 15. Hospital Pharmacies Image Figure 16. Global Acute Vulvovaginal Candidiasis Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global Acute Vulvovaginal Candidiasis Treatment Market Size (2021-2032) & (US$ Million) Figure 18. Global Acute Vulvovaginal Candidiasis Treatment Market Share by Region: 2025 VS 2032 Figure 19. Years Considered Figure 20. Global Acute Vulvovaginal Candidiasis Treatment Market Share by Players in 2025 Figure 21. Global Top 5 and 10 Acute Vulvovaginal Candidiasis Treatment Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Global Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Acute Vulvovaginal Candidiasis Treatment Revenue Market Share by Type (2021-2032) Figure 25. Global Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Acute Vulvovaginal Candidiasis Treatment Revenue Market Share by Application (2021-2032) Figure 27. North America Acute Vulvovaginal Candidiasis Treatment Market Size (2021-2032) & (US$ Million) Figure 28. North America Acute Vulvovaginal Candidiasis Treatment Market Share by Type (2021-2032) Figure 29. North America Acute Vulvovaginal Candidiasis Treatment Market Share by Application (2021-2032) Figure 30. North America Acute Vulvovaginal Candidiasis Treatment Market Share by Country (2021-2032) Figure 31. United States Acute Vulvovaginal Candidiasis Treatment Market Size (2021-2032) & (US$ Million) Figure 32. Canada Acute Vulvovaginal Candidiasis Treatment Market Size (2021-2032) & (US$ Million) Figure 33. Mexico Acute Vulvovaginal Candidiasis Treatment Market Size (2021-2032) & (US$ Million) Figure 34. Europe Acute Vulvovaginal Candidiasis Treatment Market Size (2021-2032) & (US$ Million) Figure 35. Europe Acute Vulvovaginal Candidiasis Treatment Market Share by Type (2021-2032) Figure 36. Europe Acute Vulvovaginal Candidiasis Treatment Market Share by Application (2021-2032) Figure 37. Europe Acute Vulvovaginal Candidiasis Treatment Market Share by Country (2021-2032) Figure 38. Germany Acute Vulvovaginal Candidiasis Treatment Market Size (2021-2032) & (US$ Million) Figure 39. France Acute Vulvovaginal Candidiasis Treatment Market Size (2021-2032) & (US$ Million) Figure 40. U.K. Acute Vulvovaginal Candidiasis Treatment Market Size (2021-2032) & (US$ Million) Figure 41. Italy Acute Vulvovaginal Candidiasis Treatment Market Size (2021-2032) & (US$ Million) Figure 42. Russia Acute Vulvovaginal Candidiasis Treatment Market Size (2021-2032) & (US$ Million) Figure 43. Nordic Countries Acute Vulvovaginal Candidiasis Treatment Market Size (2021-2032) & (US$ Million) Figure 44. China Acute Vulvovaginal Candidiasis Treatment Market Size (2021-2032) & (US$ Million) Figure 45. China Acute Vulvovaginal Candidiasis Treatment Market Share by Type (2021-2032) Figure 46. China Acute Vulvovaginal Candidiasis Treatment Market Share by Application (2021-2032) Figure 47. Asia Acute Vulvovaginal Candidiasis Treatment Market Size (2021-2032) & (US$ Million) Figure 48. Asia Acute Vulvovaginal Candidiasis Treatment Market Share by Type (2021-2032) Figure 49. Asia Acute Vulvovaginal Candidiasis Treatment Market Share by Application (2021-2032) Figure 50. Asia Acute Vulvovaginal Candidiasis Treatment Market Share by Country (2021-2032) Figure 51. Japan Acute Vulvovaginal Candidiasis Treatment Market Size (2021-2032) & (US$ Million) Figure 52. South Korea Acute Vulvovaginal Candidiasis Treatment Market Size (2021-2032) & (US$ Million) Figure 53. Taiwan Acute Vulvovaginal Candidiasis Treatment Market Size (2021-2032) & (US$ Million) Figure 54. Southeast Asia Acute Vulvovaginal Candidiasis Treatment Market Size (2021-2032) & (US$ Million) Figure 55. India Acute Vulvovaginal Candidiasis Treatment Market Size (2021-2032) & (US$ Million) Figure 56. Australia Acute Vulvovaginal Candidiasis Treatment Market Size (2021-2032) & (US$ Million) Figure 57. South America, Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size (2021-2032) & (US$ Million) Figure 58. South America, Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Share by Type (2021-2032) Figure 59. South America, Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Share by Application (2021-2032) Figure 60. South America, Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Share by Country (2021-2032) Figure 61. Brazil Acute Vulvovaginal Candidiasis Treatment Market Size (2021-2032) & (US$ Million) Figure 62. South Africa Acute Vulvovaginal Candidiasis Treatment Market Size (2021-2032) & (US$ Million) Figure 63. Saudi Arabia Acute Vulvovaginal Candidiasis Treatment Market Size (2021-2032) & (US$ Million) Figure 64. Turkey Acute Vulvovaginal Candidiasis Treatment Market Size (2021-2032) & (US$ Million) Figure 65. Argentina Acute Vulvovaginal Candidiasis Treatment Market Size (2021-2032) & (US$ Million) Figure 66. UAE Acute Vulvovaginal Candidiasis Treatment Market Size (2021-2032) & (US$ Million) Figure 67. Egypt Acute Vulvovaginal Candidiasis Treatment Market Size (2021-2032) & (US$ Million) Figure 68. Chile Acute Vulvovaginal Candidiasis Treatment Market Size (2021-2032) & (US$ Million) Figure 69. Research Process Figure 70. Key Executives Interviewed

Scope & coverage.

Types
  • Nystatin
  • Ketoconazole
  • Terconazole
  • Terbinafine
  • Clotrimazole
  • Fluconazole
  • Others
Applications
  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies
Companies covered
  • Sandoz International GmbH
  • Novartis AG
  • Mylan N.V.
  • Pfizer, Inc.
  • Bayer AG.
  • Scynexis, Inc
  • Phathom Pharmaceutical, Inc
  • Pacgen Life Science Corporation
  • NovaDigm Therapeutics, Inc
  • Mycovia Pharmaceuticals, Inc
  • Lupin
  • Grupo Ferrer Internacional, S.A
  • Cidara Therapeutics, Inc
  • Cadila Pharmaceuticals
  • Bristol-Myers Squibb Company
  • Basilea Pharmaceutica Ltd
  • Astellas Pharma Inc
  • Amplyx Pharmaceuticals Inc
  • Amneal Pharmaceuticals LLC
  • Accord Healthcare Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Nystatin
  5. 1.2.3 Ketoconazole
  6. 1.2.4 Terconazole
  7. 1.2.5 Terbinafine
  8. 1.2.6 Clotrimazole
  9. 1.2.7 Fluconazole
  10. 1.2.8 Others
  11. 1.3 Market Analysis by Application
  12. 1.3.1 Global Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  13. 1.3.2 Retail Pharmacies
  14. 1.3.3 Online Pharmacies
  15. 1.3.4 Hospital Pharmacies
  16. 1.4 Global Market Growth Prospects
  17. 1.5 Global Acute Vulvovaginal Candidiasis Treatment Growth Trends by Region
  18. 1.5.1 Global Acute Vulvovaginal Candidiasis Treatment Market Size by Region: 2021 VS 2025 VS 2032
  19. 1.5.2 Acute Vulvovaginal Candidiasis Treatment Market Size by Region (2021-2026)
  20. 1.5.3 Acute Vulvovaginal Candidiasis Treatment Market Size by Region (2027-2032)
  21. 1.6 Assumptions and Limitations
  22. 1.7 Study Goals and Objectives
  23. 1.8 Years Considered
2 Global Acute Vulvovaginal Candidiasis Treatment Market Dynamics
  1. 2.1 Acute Vulvovaginal Candidiasis Treatment Industry Trends
  2. 2.2 Acute Vulvovaginal Candidiasis Treatment Industry Drivers
  3. 2.3 Acute Vulvovaginal Candidiasis Treatment Industry Opportunities and Challenges
  4. 2.4 Acute Vulvovaginal Candidiasis Treatment Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Acute Vulvovaginal Candidiasis Treatment Revenue by Company (2021-2026)
  2. 3.2 Global Acute Vulvovaginal Candidiasis Treatment Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Acute Vulvovaginal Candidiasis Treatment Key Company Head office and Area Served
  4. 3.4 Global Acute Vulvovaginal Candidiasis Treatment Company, Product Type & Application
  5. 3.5 Global Acute Vulvovaginal Candidiasis Treatment Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Acute Vulvovaginal Candidiasis Treatment Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Acute Vulvovaginal Candidiasis Treatment Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Acute Vulvovaginal Candidiasis Treatment Tier 1, Tier 2, and Tier 3
4 Acute Vulvovaginal Candidiasis Treatment Market by Type
  1. 4.1 Global Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2021-2032)
  3. 4.3 Global Acute Vulvovaginal Candidiasis Treatment Market Size Share by Type (2021-2032)
5 Acute Vulvovaginal Candidiasis Treatment Market by Application
  1. 5.1 Global Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2021-2032)
  3. 5.3 Global Acute Vulvovaginal Candidiasis Treatment Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Sandoz International GmbH
  2. 6.1.1 Sandoz International GmbH Company Information
  3. 6.1.2 Sandoz International GmbH Business Overview
  4. 6.1.3 Sandoz International GmbH Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Sandoz International GmbH Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  6. 6.1.5 Sandoz International GmbH Recent Developments
  7. 6.2 Novartis AG
  8. 6.2.1 Novartis AG Company Information
  9. 6.2.2 Novartis AG Business Overview
  10. 6.2.3 Novartis AG Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Novartis AG Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  12. 6.2.5 Novartis AG Recent Developments
  13. 6.3 Mylan N.V.
  14. 6.3.1 Mylan N.V. Company Information
  15. 6.3.2 Mylan N.V. Business Overview
  16. 6.3.3 Mylan N.V. Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Mylan N.V. Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  18. 6.3.5 Mylan N.V. Recent Developments
  19. 6.4 Pfizer, Inc.
  20. 6.4.1 Pfizer, Inc. Company Information
  21. 6.4.2 Pfizer, Inc. Business Overview
  22. 6.4.3 Pfizer, Inc. Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Pfizer, Inc. Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  24. 6.4.5 Pfizer, Inc. Recent Developments
  25. 6.5 Bayer AG.
  26. 6.5.1 Bayer AG. Company Information
  27. 6.5.2 Bayer AG. Business Overview
  28. 6.5.3 Bayer AG. Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Bayer AG. Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  30. 6.5.5 Bayer AG. Recent Developments
  31. 6.6 Scynexis, Inc
  32. 6.6.1 Scynexis, Inc Company Information
  33. 6.6.2 Scynexis, Inc Business Overview
  34. 6.6.3 Scynexis, Inc Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Scynexis, Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  36. 6.6.5 Scynexis, Inc Recent Developments
  37. 6.7 Phathom Pharmaceutical, Inc
  38. 6.7.1 Phathom Pharmaceutical, Inc Company Information
  39. 6.7.2 Phathom Pharmaceutical, Inc Business Overview
  40. 6.7.3 Phathom Pharmaceutical, Inc Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Phathom Pharmaceutical, Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  42. 6.7.5 Phathom Pharmaceutical, Inc Recent Developments
  43. 6.8 Pacgen Life Science Corporation
  44. 6.8.1 Pacgen Life Science Corporation Company Information
  45. 6.8.2 Pacgen Life Science Corporation Business Overview
  46. 6.8.3 Pacgen Life Science Corporation Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Pacgen Life Science Corporation Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  48. 6.8.5 Pacgen Life Science Corporation Recent Developments
  49. 6.9 NovaDigm Therapeutics, Inc
  50. 6.9.1 NovaDigm Therapeutics, Inc Company Information
  51. 6.9.2 NovaDigm Therapeutics, Inc Business Overview
  52. 6.9.3 NovaDigm Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 NovaDigm Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  54. 6.9.5 NovaDigm Therapeutics, Inc Recent Developments
  55. 6.10 Mycovia Pharmaceuticals, Inc
  56. 6.10.1 Mycovia Pharmaceuticals, Inc Company Information
  57. 6.10.2 Mycovia Pharmaceuticals, Inc Business Overview
  58. 6.10.3 Mycovia Pharmaceuticals, Inc Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 Mycovia Pharmaceuticals, Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  60. 6.10.5 Mycovia Pharmaceuticals, Inc Recent Developments
  61. 6.11 Lupin
  62. 6.11.1 Lupin Company Information
  63. 6.11.2 Lupin Business Overview
  64. 6.11.3 Lupin Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 Lupin Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  66. 6.11.5 Lupin Recent Developments
  67. 6.12 Grupo Ferrer Internacional, S.A
  68. 6.12.1 Grupo Ferrer Internacional, S.A Company Information
  69. 6.12.2 Grupo Ferrer Internacional, S.A Business Overview
  70. 6.12.3 Grupo Ferrer Internacional, S.A Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  71. 6.12.4 Grupo Ferrer Internacional, S.A Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  72. 6.12.5 Grupo Ferrer Internacional, S.A Recent Developments
  73. 6.13 Cidara Therapeutics, Inc
  74. 6.13.1 Cidara Therapeutics, Inc Company Information
  75. 6.13.2 Cidara Therapeutics, Inc Business Overview
  76. 6.13.3 Cidara Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  77. 6.13.4 Cidara Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  78. 6.13.5 Cidara Therapeutics, Inc Recent Developments
  79. 6.14 Cadila Pharmaceuticals
  80. 6.14.1 Cadila Pharmaceuticals Company Information
  81. 6.14.2 Cadila Pharmaceuticals Business Overview
  82. 6.14.3 Cadila Pharmaceuticals Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  83. 6.14.4 Cadila Pharmaceuticals Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  84. 6.14.5 Cadila Pharmaceuticals Recent Developments
  85. 6.15 Bristol-Myers Squibb Company
  86. 6.15.1 Bristol-Myers Squibb Company Company Information
  87. 6.15.2 Bristol-Myers Squibb Company Business Overview
  88. 6.15.3 Bristol-Myers Squibb Company Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  89. 6.15.4 Bristol-Myers Squibb Company Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  90. 6.15.5 Bristol-Myers Squibb Company Recent Developments
  91. 6.16 Basilea Pharmaceutica Ltd
  92. 6.16.1 Basilea Pharmaceutica Ltd Company Information
  93. 6.16.2 Basilea Pharmaceutica Ltd Business Overview
  94. 6.16.3 Basilea Pharmaceutica Ltd Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  95. 6.16.4 Basilea Pharmaceutica Ltd Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  96. 6.16.5 Basilea Pharmaceutica Ltd Recent Developments
  97. 6.17 Astellas Pharma Inc
  98. 6.17.1 Astellas Pharma Inc Company Information
  99. 6.17.2 Astellas Pharma Inc Business Overview
  100. 6.17.3 Astellas Pharma Inc Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  101. 6.17.4 Astellas Pharma Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  102. 6.17.5 Astellas Pharma Inc Recent Developments
  103. 6.18 Amplyx Pharmaceuticals Inc
  104. 6.18.1 Amplyx Pharmaceuticals Inc Company Information
  105. 6.18.2 Amplyx Pharmaceuticals Inc Business Overview
  106. 6.18.3 Amplyx Pharmaceuticals Inc Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  107. 6.18.4 Amplyx Pharmaceuticals Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  108. 6.18.5 Amplyx Pharmaceuticals Inc Recent Developments
  109. 6.19 Amneal Pharmaceuticals LLC
  110. 6.19.1 Amneal Pharmaceuticals LLC Company Information
  111. 6.19.2 Amneal Pharmaceuticals LLC Business Overview
  112. 6.19.3 Amneal Pharmaceuticals LLC Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  113. 6.19.4 Amneal Pharmaceuticals LLC Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  114. 6.19.5 Amneal Pharmaceuticals LLC Recent Developments
  115. 6.20 Accord Healthcare Ltd
  116. 6.20.1 Accord Healthcare Ltd Company Information
  117. 6.20.2 Accord Healthcare Ltd Business Overview
  118. 6.20.3 Accord Healthcare Ltd Acute Vulvovaginal Candidiasis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  119. 6.20.4 Accord Healthcare Ltd Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  120. 6.20.5 Accord Healthcare Ltd Recent Developments
7 North America
  1. 7.1 North America Acute Vulvovaginal Candidiasis Treatment Market Size (2021-2032)
  2. 7.2 North America Acute Vulvovaginal Candidiasis Treatment Market Size by Type
  3. 7.2.1 North America Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2021-2026)
  4. 7.2.2 North America Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2027-2032)
  5. 7.2.3 North America Acute Vulvovaginal Candidiasis Treatment Market Share by Type (2021-2032)
  6. 7.3 North America Acute Vulvovaginal Candidiasis Treatment Market Size by Application
  7. 7.3.1 North America Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2021-2026)
  8. 7.3.2 North America Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2027-2032)
  9. 7.3.3 North America Acute Vulvovaginal Candidiasis Treatment Market Share by Application (2021-2032)
  10. 7.4 North America Acute Vulvovaginal Candidiasis Treatment Market Size by Country
  11. 7.4.1 North America Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2021-2026)
  13. 7.4.3 North America Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2027-2032)
  14. 7.4.4 North America Acute Vulvovaginal Candidiasis Treatment Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Acute Vulvovaginal Candidiasis Treatment Market Size (2021-2032)
  2. 8.2 Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Type
  3. 8.2.1 Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2021-2026)
  4. 8.2.2 Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2027-2032)
  5. 8.2.3 Europe Acute Vulvovaginal Candidiasis Treatment Market Share by Type (2021-2032)
  6. 8.3 Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Application
  7. 8.3.1 Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2021-2026)
  8. 8.3.2 Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2027-2032)
  9. 8.3.3 Europe Acute Vulvovaginal Candidiasis Treatment Market Share by Application (2021-2032)
  10. 8.4 Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Country
  11. 8.4.1 Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2021-2026)
  13. 8.4.3 Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2027-2032)
  14. 8.4.4 Europe Acute Vulvovaginal Candidiasis Treatment Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Acute Vulvovaginal Candidiasis Treatment Market Size (2021-2032)
  2. 9.2 China Acute Vulvovaginal Candidiasis Treatment Market Size by Type
  3. 9.2.1 China Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2021-2026)
  4. 9.2.2 China Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2027-2032)
  5. 9.2.3 China Acute Vulvovaginal Candidiasis Treatment Market Share by Type (2021-2032)
  6. 9.3 China Acute Vulvovaginal Candidiasis Treatment Market Size by Application
  7. 9.3.1 China Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2021-2026)
  8. 9.3.2 China Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2027-2032)
  9. 9.3.3 China Acute Vulvovaginal Candidiasis Treatment Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Acute Vulvovaginal Candidiasis Treatment Market Size (2021-2032)
  2. 10.2 Asia Acute Vulvovaginal Candidiasis Treatment Market Size by Type
  3. 10.2.1 Asia Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2021-2026)
  4. 10.2.2 Asia Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2027-2032)
  5. 10.2.3 Asia Acute Vulvovaginal Candidiasis Treatment Market Share by Type (2021-2032)
  6. 10.3 Asia Acute Vulvovaginal Candidiasis Treatment Market Size by Application
  7. 10.3.1 Asia Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2021-2026)
  8. 10.3.2 Asia Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2027-2032)
  9. 10.3.3 Asia Acute Vulvovaginal Candidiasis Treatment Market Share by Application (2021-2032)
  10. 10.4 Asia Acute Vulvovaginal Candidiasis Treatment Market Size by Country
  11. 10.4.1 Asia Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2021-2026)
  13. 10.4.3 Asia Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2027-2032)
  14. 10.4.4 Asia Acute Vulvovaginal Candidiasis Treatment Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst